The outcomes of this study suggest that the treatment with anti-TNF-α biologic drugs within the washout period of 12 weeks [18] (or detectable serum concentrations [21]) prior to abdominal surgery are associated with important short-term postoperative general and surgical complications for patients with IBD, in particular CD. The gene discussed is TNF; the disease is inflammatory bowel disease.